New oral anticoagulants: Better than vitamin K antagonists?;Neue orale Antikoagulanzien: Werden sie die Vitamin-K-Antagonisten verdrängen?

Internist

Volumn 51, Issue 12, 2010, Pages 1571-1581

  Voller H ^a   Alban, S ^b   Westermann, D ^c  

^a FESC   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apixaban; Atrial fibrillation; Dabigatran etexilate; Rivaroxaban; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN ETEXILATE; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN;

ANTICOAGULANT THERAPY; ARTICLE; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HIP ARTHROPLASTY; HUMAN; KNEE ARTHROPLASTY; LONG TERM CARE; PATIENT COMPLIANCE; STROKE; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTITHROMBIN PROTEINS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; ATRIAL FIBRILLATION; BENZIMIDAZOLES; HUMANS; MORPHOLINES; POSTOPERATIVE COMPLICATIONS; PYRAZOLES; PYRIDINES; PYRIDONES; STROKE; THIOPHENES; VENOUS THROMBOSIS; VITAMIN K;

EID: 78650173094     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-010-2725-z     Document Type: Article

References (0)